Filsoufi Farzan, Rahmanian Parwis B, Castillo Javier G, Karlof Eva, Schiano Thomas D, Adams David H
Department of Cardiothoracic Surgery, Division of Liver Disease, Mount Sinai School of Medicine, New York, NY 10029-1028, USA.
Liver Transpl. 2007 Sep;13(9):1317-23. doi: 10.1002/lt.21244.
Cardiovascular diseases requiring surgical therapy in patients with prior liver transplantation are rare. Little is known about the outcome of patients with liver allograft undergoing cardiac surgery. Herein we report our experience in this patient population with an emphasis on operative outcomes and mid-term survival. Between January 1998 and December 2004, 12 patients (mean +/- standard deviation age 68 +/- 9 years, 7 [58%] male) with previous liver transplantation who underwent cardiac surgery were identified. Main outcome measures were hospital mortality, postoperative complications, allograft function, and long-term survival. There was no in-hospital mortality. Three major complications (25%) occurred, including 1 each (8%) of respiratory failure, renal failure, and biliary leakage. All complications were resolved by the time of discharge. Allograft dysfunction determined by an increase of liver function parameters was noticed in 4 (33%) and recovered before discharge. The average length of stay in intensive care unit was 72 +/- 45 hours, and the mean length of stay in hospital was 22 +/- 17 days. One- and 5-year survival was 91% +/- 8% and 67% +/- 14%, respectively. Cardiac surgery can be performed safely in liver transplant recipients with extremely low mortality and acceptable morbidities. Allograft dysfunction is a common finding, but it is transient, with early functional recovery. Five-year survival of liver recipients undergoing cardiac procedures is similar to that of the general population undergoing cardiac surgery. Our data suggest that these patients should be considered for cardiac surgery in reference centers with expertise in complex cardiac procedures and perioperative management of these highly specific patients.
既往有肝移植史的患者中需要手术治疗的心血管疾病较为罕见。对于接受心脏手术的肝移植受者的预后了解甚少。在此,我们报告我们在这一患者群体中的经验,重点是手术结果和中期生存率。1998年1月至2004年12月期间,确定了12例既往有肝移植史且接受心脏手术的患者(平均年龄±标准差为68±9岁,7例[58%]为男性)。主要观察指标为住院死亡率、术后并发症、移植肝功能和长期生存率。无住院死亡病例。发生了3例主要并发症(25%),包括呼吸衰竭、肾衰竭和胆漏各1例(8%)。所有并发症在出院时均已解决。4例(33%)出现肝功能参数升高所确定的移植肝功能障碍,出院前恢复。重症监护病房的平均住院时间为72±45小时,住院平均时间为22±17天。1年和5年生存率分别为91%±8%和67%±14%。心脏手术可在肝移植受者中安全进行,死亡率极低且发病率可接受。移植肝功能障碍是常见现象,但为一过性,功能早期恢复。接受心脏手术的肝移植受者的5年生存率与接受心脏手术的普通人群相似。我们的数据表明,对于这些患者,应在具备复杂心脏手术专业知识和这些高度特殊患者围手术期管理经验的参考中心考虑进行心脏手术。